The funding will be used to advance Avammune's assets for cancer and autoimmune illnesses, according to the business.

"We are creating a revolutionary class of medications that harness the body's first line of defense against infections to attack cancer," says Dr. Aditya Kulkarni, Chief Scientific Officer of Avammune. These extremely powerful medications have the ability to overcome drug resistance and, due to their chemical composition, may be administered to patients as oral tablets, making them potentially more cheap alternatives to biological treatments."

Avammune is in active discussions with large pharmaceutical and biotech businesses about collaborating on clinical translation of the assets, as well as with strategic investors about bringing the assets through clinical testing independently.

Arun B Papaiah, CEO, Avammune said, “Avammune’s technology platform has been validated in various animal models and is gearing up for safety studies. With the influx of funding, we are hoping to complete these safety studies and are gearing up for partnerships for entering clinical testing next year. This latest round of funding will also allow us to further strengthen our diversified pipeline of drugs for cancers and autoimmune diseases. It is a pleasure working with The Chennai Angels who join existing and other new investors and are excited to bring them on board as partners.”

Avammune is in advanced talks with large pharmaceutical and biotech businesses about collaborating on clinical translation of the assets, as well as with strategic investors about bringing the assets through clinical testing independently.

According to Sameer Mehta, Director of Mehta's Multispecialty Hospital India Pvt Ltd and Lead Investor from The Chennai Angels, despite remarkable advances in the discovery and development of new cancer therapies, the illness continues to impact millions each year. TCA is excited to be a part of Avammune's Immuno-oncology asset development.